AQRT could see its addressable market double if its planned Phase 2 vitiligo study advances in 4Q26, according to Agora Trading’s Michael Taylor. He says the indication represents a $1 billion market and is not reflected in current pricing.
published
AQRT could see its addressable market double if its planned Phase 2 vitiligo study advances in 4Q26, according to Agora Trading’s Michael Taylor. He says the indication represents a $1 billion market and is not reflected in current pricing.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.